Hence, these findings elucidated a novel signaling complex centered around <i>circESR1</i> and HNRNPAB in ER+ breast cancer, and suggested that <i>circESR1</i> might represent a potential therapeutic target for this disease. Here, HNRNPAB is linked to breast carcinoma.